Abeona Therapeutics (ABEO)

May 16, 2025, 1:37 AM EDT - 1 day ago

Abeona Therapeutics Inc. (ABEO) Q1 2025 Earnings Call Transcript

May 15, 2025, 7:30 AM EDT - 1 day ago

Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates

May 14, 2025, 8:07 AM EDT - 2 days ago

UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder

May 14, 2025, 7:30 AM EDT - 2 days ago

Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder

May 14, 2025, 7:30 AM EDT - 2 days ago

Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder

May 12, 2025, 7:30 AM EDT - 4 days ago

Abeona Therapeutics® Enters into Agreement to Sell Priority Review Voucher for $155 Million

May 7, 2025, 4:59 PM EDT - 9 days ago

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 30, 2025, 4:41 PM EDT - 16 days ago

Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease

Apr 29, 2025, 6:06 AM EDT - 17 days ago

US FDA approves Abeona's skin disorder therapy

Apr 29, 2025, 6:00 AM EDT - 17 days ago

U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Apr 27, 2025, 8:30 AM EDT - 19 days ago

Undercovered Dozen: 3D Systems, Seritage, Topicus, Timken +

DDD TKR KARO NNDM ORC PAA PAGP

Apr 21, 2025, 10:00 AM EDT - 25 days ago

Pz-Cel Has Massive Potential For RDEB Patients

Apr 12, 2025, 11:39 AM EDT - 4 weeks ago

Abeona Therapeutics: A Buy With Major PDUFA Catalyst On April 29 That Should Send Shares Higher

Mar 20, 2025, 3:20 PM EDT - 2 months ago

Abeona Therapeutics Inc. (ABEO) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 7:30 AM EDT - 2 months ago

Abeona Therapeutics® Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans

Mar 4, 2025, 9:00 AM EST - 2 months ago

Abeona Therapeutics® to Present at the Leerink Partners Global Healthcare Conference

Jan 24, 2025, 12:40 PM EST - 4 months ago

Abeona Therapeutics: Despite Some Competitive Pressure, This Looks Undervalued

Nov 14, 2024, 7:30 AM EST - 6 months ago

Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Nov 12, 2024, 7:30 AM EST - 6 months ago

Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa

Nov 4, 2024, 7:30 AM EST - 6 months ago

Abeona Therapeutics® Announces Participation in November Investor Conferences

Oct 29, 2024, 7:30 AM EDT - 7 months ago

Abeona Therapeutics® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration

Oct 3, 2024, 8:09 AM EDT - 8 months ago

Abeona Therapeutics Targets RDEB Market With Promising Pz-cel Therapy

Sep 3, 2024, 7:30 AM EDT - 9 months ago

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

Aug 14, 2024, 7:30 AM EDT - 9 months ago

Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors

Aug 13, 2024, 7:30 AM EDT - 9 months ago

Abeona Therapeutics® Announces Favorable Medicare Reimbursement Decisions for Pz-cel

Aug 12, 2024, 7:30 AM EDT - 9 months ago

Abeona Therapeutics® Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission

Jul 12, 2024, 4:59 PM EDT - 11 months ago

Abeona: BLA Resubmission Of Pz-Cel Gets Ball Rolling Towards Other Milestones

Jul 11, 2024, 7:30 AM EDT - 11 months ago

Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204 Capsid for Select Ophthalmology Indications

Jul 8, 2024, 7:30 AM EDT - 11 months ago

Abeona Therapeutics to Present at the Stifel Virtual Cell Therapy Forum

Jun 3, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 28, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics to Present at the Jefferies Global Healthcare Conference

May 15, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Progress

May 3, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

May 2, 2024, 5:50 PM EDT - 1 year ago

Buying The Dip In Abeona Therapeutics After The Recent Manufacturing-Related CRL

May 2, 2024, 11:00 AM EDT - 1 year ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Abeona Therapeutics Inc. (ABEO) on Behalf of Investors

Apr 29, 2024, 7:11 PM EDT - 1 year ago

The Law Offices of Frank R. Cruz Announces Investigation of Abeona Therapeutics Inc. (ABEO) on Behalf of Investors

Apr 23, 2024, 5:20 PM EDT - 1 year ago

Abeona Therapeutics Tanks On CRL From The FDA, But All Hope Is Not Lost

Apr 22, 2024, 4:31 PM EDT - 1 year ago

US FDA declines to approve Abeona's skin disorder treatment

Apr 22, 2024, 4:05 PM EDT - 1 year ago

Abeona Therapeutics Provides Regulatory Update on Pz-cel

Mar 18, 2024, 7:30 AM EDT - 1 year ago

Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections

Feb 1, 2024, 7:30 AM EST - 1 year ago

Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)

Jan 8, 2024, 7:30 AM EST - 1 year ago

Abeona Therapeutics Announces $50 Million Credit Facility

Nov 27, 2023, 7:30 AM EST - 1 year ago

Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)

Nov 16, 2023, 4:26 PM EST - 1 year ago

Abeona Therapeutics Inc. (ABEO) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 7:30 AM EST - 1 year ago

Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments

Sep 26, 2023, 7:30 AM EDT - 1 year ago

Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa

Sep 12, 2023, 7:30 AM EDT - 1 year ago

Abeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial Officer